Flash K.O. Before the Super Bowl! Hims & Hers Halts Cheap Wegovy After Massive FDA Threats!
Reading Time: 3 minutes
The dream of an affordable weight-loss pill has burst for now. What began as a disruptive assault on the billion-dollar monopoly of Novo Nordisk and Eli Lilly ended for telemedicine provider Hims & Hers (HIMS) in a fiasco. After announcing a $49 alternative to Wegovy, the pharmaceutical giants and US authorities, including the FDA, struck back with full force. We illuminate the dramatic retreat, the stock crash, and the bitter irony of a Super Bowl advertisement that may now fall flat. The stock dropped over 13% in pre-market trading. Billion-Dollar...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
